Retatrutideyog ib qho tshiab triple receptor agonist uas tsom rau GIP, GLP-1, thiab glucagon receptors ib txhij. Nws tswj cov ntshav qab zib, ua rau lub plab zom mov qeeb, thiab txhawb nqa lub zog siv zog los ntawm kev sib koom ua ke . 10mg yog ib theem tseem ceeb ntawm kev tshawb fawb hauv kev sim tshuaj ntawm cov tshuaj no, ua rau nws muaj peev xwm tswj tau qhov hnyav thiab tswj ntshav qab zib. Cov kev tshawb fawb tau pom tias ntawm qhov ntau npaum li cas, cov tshuaj tuaj yeem txo qhov hnyav ntawm cov neeg mob rog lossis rog rog thiab txhim kho glycated hemoglobin qib ntawm cov neeg mob ntshav qab zib hom 2. Nws qhov kev poob phaus ua tau zoo tshaj qhov tam sim no tseem ceeb ntawm ib leeg lossis dual receptor agonists. Nws cov kev mob tshwm sim feem ntau zoo ib yam li lwm cov tshuaj zoo sib xws, feem ntau suav nrog kev mob plab hnyuv, tab sis feem ntau yog me me mus rau nruab nrab thiab tuaj yeem hloov kho nrog kev kho mob tas li. Raws li kev ua tiav hauv kev kho cov kab mob metabolic, 10mg ntawm rettrutide sawv cev rau cov kev taw qhia tseem ceeb rau cov tiam tom ntej ntawm ntau hom kev kho mob thiab ua rau muaj kev cia siab tshiab rau ntau pua lab tus neeg mob thoob ntiaj teb.
|
|
|
|
|
|
|
|
Yeeb Yam Keeb Kwm thiab Mechanism of Action
Retatrutide (LY-3437943) yog GLP-1 / GIP / Glucagon triple receptor agonist tsim los ntawm Eli Lilly hauv Tebchaws Meskas. Nws belongs rau tiam tshiab ntawm metabolic regulatory peptide tshuaj. Lub hauv paus kev tsim kho tshiab nyob hauv ib txhij ua kom muaj peb qhov tseem ceeb cov tshuaj hormones receptors:
GLP-1 receptors:Txhawb nqa insulin secretion, inhibits glucagon tso tawm, qeeb plab hnyuv plab, yog li txo cov ntshav qab zib thiab txo qis qab los noj mov.
GIP receptor:Txhim kho insulin rhiab heev, tswj cov roj metabolism, thiab inhibits rog rog.
Glucagon receptor:Txhawb kev rog rog thiab kev siv zog, thaum tswj cov ntshav qab zib kom ruaj khov.
Los ntawm cov teebmeem kev sib koom ua ke, Retatrutide ua tiav ntau- lub hom phiaj kev tswj hwm ntawm cov metabolism, rhuav tshem cov kev txwv ntawm ib txwm siv - lub hom phiaj lossis dual - cov tshuaj (xws li GLP-1 analogues), muab lub tswv yim tshiab rau kev kho mob rog rog, ntshav qab zib thiab cov kab mob metabolic.
Kev tshawb fawb thiab kev tsim kho txheej txheem thiab kev sim tshuaj
Kev txhim kho ntawm Retatrutide pib nrog rau hauv - kev tshawb nrhiav qhov tob ntawm cov kab mob metabolic syndrome. Eli Lilly, dhau los ntawm kev tsim qauv molecular optimization, ua tiav qhov no triple agonist thiab maj mam nce mus rau hauv kev sim tshuaj:
Theem 1 sim:Txhawm rau txheeb xyuas cov yam ntxwv ntawm kev nyab xeeb thiab cov tshuaj pharmacokinetic, nws tau pom tias ib nrab ntawm - lub neej tom qab kev tswj hwm ib leeg yog kwv yees li 6 hnub, txhawb nqa ib zaug - noj tshuaj txhua lub lim tiam.
Theem 2 sim:Txhawm rau ntsuas kev ua tau zoo ntawm cov neeg rog rog lossis rog rog, cov txiaj ntsig tau raws li hauv qab no:
24 lub lis piam: Cov koob tshuaj ntau tshaj plaws (12mg) ua tiav qhov hnyav poob ntawm 17.5%.
48 lub lis piam: Qhov nruab nrab qhov hnyav poob mus txog 24.2%, ua tau zoo dua rau pawg tswj hwm (cov pab pawg placebo nrog 2.1% poob phaus).
Cov ntsuas metabolic tau txhim kho: ntshav qab zib, ntshav lipids, ntshav siab, thiab lwm yam tau ua kom zoo dua.
Theem 3 sim:Tam sim no tab tom ua haujlwm, tsom mus rau qhov ntev -kev nyab xeeb thiab cov txiaj ntsig ntawm cov hlab plawv, xav tias yuav ua tiav hauv 2026-2027.
Chaw kho mob thiab qhov zoo ntawm Retatrutide 10mg
Kev xaiv koob tshuaj
Hauv Theem 2 mus sib hais, koob tshuaj 10mg tau raug pov thawj los ua qhov sib npaug ntawm qhov ua tau zoo thiab kev nyab xeeb:
Cov nyhuv poob: Cov 10mg pab pawg tau ua tiav 22.5% qhov hnyav tshaj 48 lub lis piam, uas yog ze rau 24.2% ntawm cov koob tshuaj ntau tshaj (12mg). Txawm li cas los xij, qhov tshwm sim ntawm kev mob tshwm sim qis dua.
Kev Nyab Xeeb: Qhov tshwm sim ntawm kev mob plab hnyuv (xws li xeev siab thiab raws plab) nce ntxiv nrog cov koob tshuaj. Pab pawg 10mg muaj kev ua siab ntev zoo dua li 12mg pawg.
Ua raws li: Ib zaug - txhaj tshuaj subcutaneous txhua lub lim tiam yog qhov yooj yim rau kev khiav lag luam thiab tau txais txiaj ntsig zoo rau cov neeg mob.
Core zoo
Ntau - lub hom phiaj sib koom ua ke: Nws tswj cov ntshav qab zib, rog metabolism thiab lub zog sib npaug ib txhij, ua tiav "ib yam tshuaj rau ntau yam".
Kev poob ceeb thawj tseem ceeb: Cov ntaub ntawv Phase 2 qhia tau hais tias pawg 10mg tau ua tiav qhov hnyav dua li GLP-1 analogues uas twb muaj lawm (xws li 2.4mg pawg ntawm semaglutide, nrog rau 10-15% qhov hnyav tshaj 68 lub lis piam).
Kev txhim kho metabolic zoo: Nws tsis yog tsuas yog txo qhov hnyav xwb tab sis kuj txo qis kev pheej hmoo ntawm cov hlab plawv thiab txhim kho tsis yog - kab mob cawv fatty siab (NAFLD) thiab lwm yam teeb meem metabolic.
Ntev - lub sijhawm muaj peev xwm: Theem 3 kev sim yuav ntxiv txheeb xyuas nws cov kev tiv thaiv kab mob plawv thiab kev tiv thaiv ntshav qab zib.
Clinical application scenarios thiab hom phiaj pej xeem
Kev kho mob rog
Cov neeg siv tau: BMI Ntau dua lossis sib npaug li 30 kg / m², lossis BMI Ntau dua lossis sib npaug li 27 kg / m² nrog cov teeb meem (xws li kub siab, hyperlipidemia, NAFLD).
Qhov zoo: Rau cov neeg mob uas tsis zoo rau cov kev kho mob ib txwm muaj (xws li kev cuam tshuam hauv kev ua neej, ib zaug - cov tshuaj siv), Retatrutide 10mg tuaj yeem muab kev txhawb zog kom poob phaus.
Kev tswj ntshav qab zib hom 2
Cov pej xeem siv tau: Cov neeg mob ntshav qab zib hom 2 uas tswj ntshav qab zib tsis zoo (HbA1c Ntau dua lossis sib npaug li 7%), tshwj xeeb tshaj yog cov neeg rog rog.
Qhov zoo: Los ntawm kev txhawb nqa cov tshuaj insulin secretion thiab inhibiting glucagon tso tawm, nws ua tiav ob txoj kev tswj cov ntshav qab zib thiab qhov hnyav, txo cov koob tshuaj insulin thiab kev pheej hmoo ntawm hypoglycemia.
Cov kab mob metabolic- ntsig txog
Tsis yog -Alcoholic fatty siab kab mob (NAFLD): Retatrutide tuaj yeem txo cov rog hauv siab thiab txhim kho daim siab ua haujlwm.
Kev tiv thaiv kab mob plawv: Los ntawm kev poob phaus, txo lipid, txo ntshav siab thiab lwm yam, nws txo qhov kev pheej hmoo ntawm atherosclerotic cardiovascular disease (ASCVD).
Kev nyab xeeb thiab kev mob tshwm sim
Cov teebmeem tshwm sim
Gastrointestinal cov tshuaj tiv thaiv:xeev siab (60-70%), raws plab (30-40%), ntuav (20-30%), uas feem ntau tshwm sim nyob rau theem pib ntawm kev kho mob thiab maj mam txo lub sijhawm.
Qhov chaw txhaj tshuaj tiv thaiv:Liab, khaus, thiab lwm yam, nrog rau qhov tshwm sim ntawm li 10-15%.
Hypoglycemia:Tsis tseem ceeb thaum siv ib leeg, tab sis yuav tsum tau ceev faj thaum ua ke nrog sulfonylurea lossis insulin.
Cov tswv yim tswj kev pheej hmoo
Dose titration:Pib los ntawm koob tshuaj tsawg (xws li 1mg), maj mam nce mus rau lub hom phiaj koob tshuaj (xws li 10mg) txhua 4 lub lis piam kom txo cov kev mob tshwm sim.
Kev kawm tus neeg mob:Qhia cov neeg mob kom kho lawv cov kev noj haus (xws li txo kev noj cov zaub mov muaj roj ntau-), siv sijhawm noj mov, thiab qhia lawv txog lub sijhawm xav tau thiab cov kev pab cuam rau cov kev mob tshwm sim.
Saib xyuas thiab ua raws-up:Tsis tu ncua ntsuas cov ntshav qab zib, daim siab thiab lub raum ua haujlwm, thiab electrolytes, thiab kho cov phiaj xwm kho mob sai.
Kev lag luam zeem muag thiab kev sib tw toj roob hauv pes
Kev lag luam xav tau
Lub ntiaj teb kev kis ntawm kev rog thiab ntshav qab zib tau nce ntxiv. Nws tau kwv yees tias cov neeg rog rog hauv ntiaj teb yuav ncav cuag 1 billion hauv 2030, thiab tus naj npawb ntawm cov neeg mob ntshav qab zib hom 2 yuav ncav cuag 640 lab. Retatrutide, nrog nws qhov hnyav poob thiab muaj peev xwm txhim kho metabolic, xav tias yuav dhau los ua cov tshuaj blockbuster tom ntej.
Kev Ntsuam Xyuas Kev Sib Tw
Cov kev kho mob uas twb muaj lawm:GLP-1 analogues (xws li semaglutide, teplizumab) ua lag luam, tab sis lawv cov txiaj ntsig poob qis yog txwv (li 10-15%).
Hauv Kev Txhim Kho Tshuaj:
Tirzepatide (teplizumab):Ib tug dual GLP-1 / GIP agonist. Theem 3 kev sim qhia tau hais tias pawg 15mg tau ua tiav 22.5% poob phaus hauv 72 lub lis piam, zoo ib yam li cov nyhuv ntawm Retatrutide 10mg, tab sis Retatrutide tuaj yeem muab cov txiaj ntsig metabolic ntxiv los ntawm kev ua kom Glucagon receptor.
Lwm Triple -Tsev Tshuaj:Xws li Masudotide (GLP-1/GCGR dual lub hom phiaj), tab sis triple-targeted synergy tsis tau muaj pov thawj.
Cov kev sib tw thiab cov kev taw qhia yav tom ntej
Ntev -Kev Tshawb Fawb Txog Kev Nyab Xeeb
Kev sim Phaj 3 yog tsim nyog los xyuas kom meej tias Retatrutide ua rau muaj kev pheej hmoo ntawm medullary thyroid cancer (MTC) lossis pancreatitis (muaj kev txhawj xeeb zoo ib yam li GLP-1 analogues), txawm hais tias cov ntaub ntawv tam sim no tsis qhia cov cim tseem ceeb.
Kev tshawb fawb txog Cov Neeg Tshwj Xeeb
Nws yog ib qho tsim nyog los tshawb txog qhov ua tau zoo thiab kev nyab xeeb ntawm Retatrutide hauv cov menyuam yaus, cov neeg laus, thiab cov neeg mob lub raum tsis txaus, txhawm rau nthuav dav nws cov ntawv thov.
Kev Tshawb Fawb Kev Sib Txuas
Kev sib xyaw nrog SGLT-2 inhibitors, basal insulin, lossis lwm yam tshuaj tiv thaiv kab mob metabolic tuaj yeem txhim kho cov txiaj ntsig kho mob ntxiv, tab sis qhov kev pheej hmoo ntawm cov kev mob tshwm sim yuav tsum sib npaug.
Nqi thiab Kev Siv Tau
Raws li cov khoom siv roj ntsha tshiab, tus nqi ntawm Retatrutide kuj yuav siab heev. Txhawm rau txhim kho kev nkag tau yooj yim, nws yuav tsum tau sib tham los ntawm kev pov hwm kho mob lossis siv cov kev pab cuam rau cov neeg mob.
Xaus
Retatrutide 10mg sawv cev rau kev ua tiav tseem ceeb hauv kev kho cov kab mob metabolic. Nws triple receptor activation mechanism muab cov kev daws teeb meem tshiab rau kev rog rog, ntshav qab zib thiab lwm yam teeb meem. Txawm hais tias ntev - cov ntaub ntawv tseem xav tau los txheeb xyuas nws txoj kev nyab xeeb thiab kev tiv thaiv kab mob plawv, cov kev sim tshuaj uas twb muaj lawm tau ua pov thawj tag nrho nws lub peev xwm. Nrog rau kev nce qib ntawm Theem 3 mus sib hais, Retatrutide xav tias yuav dhau los ua lwm yam "blockbuster" tshuaj rau Eli Lilly hauv 2027, hloov kho thaj chaw ntawm kev kho mob metabolic thiab nqa cov txiaj ntsig rau cov neeg mob thoob ntiaj teb.